Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16489245 | 0.88 | KMT2A (0.44) | NPC1TSHRL3MBTL1LMNARXFP1 | |
| SCHEMBL16489225 | 0.84 | NPC1 (0.73) | NPC1TSHRL3MBTL1RXFP1PPARG | |
| SCHEMBL16489211 | 0.78 | GRM4 (0.55) | NPC1L3MBTL1LMNARAB9AKMT2A | |
| SCHEMBL16489229 | 0.78 | ALDH1A1 (0.46) | NPC1L3MBTL1LMNARAB9AKMT2A | |
| SCHEMBL16489224 | 0.77 | GRM4 (0.41) | NPC1TSHRRAB9AKMT2AALDH1A1 | |
| SCHEMBL16489241 | 0.77 | MAPT (0.46) | NPC1TSHRL3MBTL1LMNARAB9A | |
| SCHEMBL16489220 | 0.77 | GRM4 (0.40) | NPC1TSHRL3MBTL1LMNARXFP1 | |
| SCHEMBL17064041 | 0.77 | NPC1 (0.51) | NPC1TSHRL3MBTL1LMNARXFP1 | |
| SCHEMBL16491917 | 0.73 | KMT2A (0.50) | NPC1TSHRL3MBTL1RXFP1RAB9A | |
| SCHEMBL16491940 | 0.72 | PPARG (0.45) | NPC1TSHRLMNARXFP1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10653673-B2 | Substituted imidazoles as N-type calcium channel blockers | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-19 | — | — | US | disclosed |
| US-20180161312-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-14 | — | — | US | disclosed |
| US-20180161312-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-14 | — | — | US | disclosed |
| US-9974775-B2 | Substituted imidazoles as N-type calcium channel blockers | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-22 | — | — | US | disclosed |
| US-9974775-B2 | Substituted imidazoles as N-type calcium channel blockers | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-22 | — | — | US | disclosed |
| US-20160310468-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2016-10-27 | — | — | US | disclosed |
| US-20160310468-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2016-10-27 | — | — | US | disclosed |
| US-9453002-B2 | Substituted imidazoles as N-type calcium channel blockers | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-27 | — | — | US | disclosed |
| US-9453002-B2 | Substituted imidazoles as N-type calcium channel blockers | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-27 | — | — | US | disclosed |
| US-20150051225-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-19 | — | — | US | disclosed |
| US-20150051225-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051225-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1B, CACNA1E, CACNA1S | NPC1 643/4885TSHR 2085/4885L3MBTL1 2423/4885 |
| US-10653673-B2 | Substituted imidazoles as N-type calcium channel blockers | CACNA1B, CACNA1E, CACNA1S | NPC1 643/4885TSHR 2085/4885L3MBTL1 2423/4885 |
| US-20180161312-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1B, CACNA1E, CACNA1S | NPC1 643/4885TSHR 2085/4885L3MBTL1 2423/4885 |
| US-20160310468-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1B, CACNA1E, CACNA1S | NPC1 643/4885TSHR 2085/4885L3MBTL1 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.